THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the Reprieve DMS.

Dr James Udelson (Tufts Medical Center, Boston, MA, US) joins us to discuss the findings from FASTR (NCT05174312), a prospective, randomized, phase-two, pilot trial investigating the Reprieve DMS in comparison to optimal diuretic therapy for ADHF patients. The primary efficacy endpoint was the total urine sodium output, and the primary safety endpoint includes clinically significant acute kidney injury, severe electrolyte abnormality, symptomatic hypotension or hypertensive emergency.

Interview Questions:
1. What is the importance behind the FASTR trial?
2. What was the study design and patient population?
3. What were the key findings?
4. How should these findings impact clinical practice?
5. What further research is needed?

Recorded remotely from Boston, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.